TAPP Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sofradim Production
ClinicalTrials.gov Identifier:
NCT01481376
First received: October 24, 2011
Last updated: April 4, 2013
Last verified: April 2013

October 24, 2011
April 4, 2013
October 2011
October 2011   (final data collection date for primary outcome measure)
Proportion of subjects who experience hernia recurrence (defect treated initially with Parietex™ ProGrip™) within 12 months post-surgery. [ Time Frame: At least 12 months post-surgery ] [ Designated as safety issue: Yes ]
Recurrence is defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin. The recurrence symptoms are assessed by phone based on the Symptoms Questionnaire and the recurrence diagnosis is confirmed during a physical examination by a physician.
Same as current
Complete list of historical versions of study NCT01481376 on ClinicalTrials.gov Archive Site
  • Incidence of Groin Pain (pain score 0-10) [ Time Frame: The day of the discharge (an expected average of 1 day), 1month and at least 12 month post-operatively ] [ Designated as safety issue: Yes ]
  • Analgesic use [ Time Frame: The day of the discharge (an expected average of 1 day), 1month and at least 12 month post-operatively ] [ Designated as safety issue: No ]
  • Postoperative complications including, infection, seroma, hematoma, visceral adherence, allergy etc [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
  • Patient satisfaction [ Time Frame: at least 12 month post-operatively ] [ Designated as safety issue: No ]
  • Operative time [ Time Frame: From skin incision to closure (The expected median operating time is 36 minutes for unilateral and 50 minutes for bilateral repair) ] [ Designated as safety issue: No ]
  • Hospital length of stay [ Time Frame: Duration of the hospital stay (expected average of 1 day) ] [ Designated as safety issue: No ]
  • Incidence of Groin Pain (pain score 0-10) [ Time Frame: The day of the discharge (an expected average of 1 day), 1month and at least 12 month post-operatively ] [ Designated as safety issue: Yes ]
  • Analgesic use [ Time Frame: The day of the discharge (an expected average of 1 day), 1month and at least 12 month post-operatively ] [ Designated as safety issue: No ]
  • Postoperative complications including, infection, seroma, hematoma, visceral adherence, allergy etc [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
  • Patient satisfaction [ Time Frame: at least 12 month post-operatively ] [ Designated as safety issue: No ]
  • Operative time [ Time Frame: From skin incision to closure ] [ Designated as safety issue: No ]
  • Hospital length of stay [ Time Frame: Duration of the hospital stay (expected average of 1 day) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
TAPP Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh
Laparoscopic Transabdominal Preperitoneal (TAPP) Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh: A Retrospective Study With 12 Month Follow-up

The objective of this retrospective study is to evaluate the postoperative clinical outcomes at discharge, 1 month and 12 months, associated with the use of Parietex™ ProGrip™ in Laparoscopic Transabdominal preperitoneal inguinal hernia repair. Results from this study will be used to support the short- and long-term clinical outcomes of Parietex™ ProGrip™ when used in inguinal hernia repair by laparoscopic approach.

  • Single center study
  • Population: All subjects have undergone Laparoscopic Transabdominal preperitoneal surgical treatment for inguinal hernia repair with Parietex™ ProGrip™ without additional fixation between September 2008 and March 2010 (inclusive) with at least 12 months of follow-up.

The primary outcome:

• Proportion of subjects who experience hernia recurrence (defect treated initially with Parietex™ ProGrip™) within 12 months post-surgery.

Recurrence is defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin.

The recurrence symptoms are assessed by phone based on the Symptoms Questionnaire and the recurrence diagnosis is confirmed during a physical examination by a physician and defined as a clinically manifest bulge or a protrusion exacerbated by a Valsalva maneuver in the operated groin. If subject has a surgical repair of the hernia within the 12 month postoperative period, it will be documented as evidence of hernia recurrence.

The secondary outcome:

  • Incidence of Groin Pain (pain score 0-10) and analgesic use at discharge, 1 month and 12 month postoperatively
  • Incidence of postoperative complications including, wound infection (any infection of the incision), mesh infection (an infection of the mesh), bleeding, mesh migration, mesh erosion, fistula, small bowel obstruction, seroma, hematuria, hematoma, inflammation, chronic pains/ inguinodynia, infection, visceral adherence, allergic reactions to the components of the product at discharge, 1month and 12 month post-operatively
  • Patient satisfaction
  • Operative time
  • Hospital length of stay
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

All subjects have undergone Laparoscopic Transabdominal preperitoneal surgical treatment for inguinal hernia repair with Parietex™ ProGrip™ without additional fixation between September 2008 and March 2010 (inclusive) with at least 12 months of follow-up. Subjects must meet the protocol outlined eligibility criteria to be included in the study.

Postoperative Complications
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
169
April 2013
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The following diagnosis will be included:

    • Inguinal hernia: unilateral or bilateral

All subjects must meet the following inclusion criteria:

  • ≥18 years of age
  • Had undergone elective (non-emergent) primary surgical repair of the above diagnosis with Parietex ProGrip™ by Laparoscopic Transabdominal preperitoneal inguinal hernia repair between September 2008 to March 2010
  • Post-operative follow-up ≥ 12 months or recurrence which occurs within the 12 months post-surgery (If subject has a known incidence of recurrence before the 12 months follow up, the subject will be included in the study.)

Exclusion Criteria:

  • Subjects who meet any of the following exclusion criteria are not eligible for study participation:

    • Patients with previous laparoscopic Inguinal hernia repair
    • Emergency procedures
    • Patients with incarcerated hernias
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01481376
COVPTAP0161
No
Sofradim Production
Sofradim Production
Not Provided
Principal Investigator: Dieter BIRK, MD Evangelisches Krankenhaus Zweibrücken - Obere Himmelsbergstr. 38 - 66482 Zweibrücken - GERMANY
Sofradim Production
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP